An observational study in Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL), sponsored by International Extranodal Lymphoma Study Group (IELSG). Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy — 31 open to participants now, 51 under way, 12 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Italy.
Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, this one is the 14th largest by planned enrollment of the 22 observational ones that give a count, is one of 2 that started in 2027, is one of 22 observational ones, reaches primary completion later than 47 of the 50 other live ones, and was the 156th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →31 of the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, France and 5 more countries
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 41
First in 1994; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 186 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 124 across the 143 interventional studies, 163 across the 22 observational. Of the 101 that completed or were terminated, 51 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 166 have an industry lead sponsor. The 10 most frequent:
International Extranodal Lymphoma Study Group (IELSG) is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
International Extranodal Lymphoma Study Group (IELSG) has 3 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
15 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04442022Phase 3Karyopharm Therapeutics IncA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | 2026-12 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05139017Phase 3Merck Sharp & Dohme LLCA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | 2027-09-24 |
| NCT07393204Andrés José Maria FerreriItalian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL | 2026-12-10 |
Add all 15 to your calendar (.ics) → With an account.
Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.
Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' medical charts or electronic medical records upon receipt of ethical approval. Each patient enrolled in the study will be assigned a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data and to label biological samples. The coded biological material will be transferred at the Institute of Oncology Research in Bellinzona and the IRCCS Policlinico San Matteo Foundation in Pavia.
Diagnostic slides will be centrally revised by a panel of expert pathologists to confirm the diagnosis of PCNS-DLBCL. Health-related data will be collected in the e-CRFs. Data quality will be ensured by query generation.
Annotated baseline features will include: age, sex, the date of diagnosis, ECOG PS, IELSG index, clinical features (i.e. neurologic signs or symptoms, psychiatric and behavioural changes, systemic lymphoma symptoms, and comorbidities), imaging features (i.e. MRI report), disease involvements (i.e. bone marrow infiltrate, CSF, Vitro-retinal, basal ganglia, corpus callosum, brain stem, or cerebellum), laboratory features (i.e. complete blood count parameters, LDH levels, HIV infection evidence, HCV infection evidence, HBV infection evidence, EBV infection evidence, CMV infection evidence, and cerebrospinal fluid examination parameters).
Annotated follow-up features will include: the start date, the regimen, the response level and the date of response evaluation of the first-line therapy, the start date, the regimen, the response level and the date of response evaluation of the second-line therapy; the date of transplantation and the date of relapse.
Survival features will include date of death, cause of death, and date of last follow-up.
All FFPE samples will undergo a comprehensive histological review, including immunohistochemical investigations aimed to analyze the various cell populations and the microenvironment; EBER ISH assay to verify the presence of latent EBV-infection, FISH assays to verify the presence of translocations involving BCL2, BCL6, and MYC genes, and of CDKN2A and 6p21-22 (HLA locus) loss.
Molecular analyses on tumor samples will include: 1) DNA alteration analysis by means of NGS approach; 2) genome-wide methylation profiling (the sole epigenetic fingerprints that can be robustly assayed on FFPE material); 3) transcriptional profiling; 4) Ig heavy chain (IGH) rearrangements detection and immunoglobulin heavy-chain variable region gene (IGHV) analysis.
The results of all these analyses will be recorded in the clinical-biological database. Statistical analysis will be performed to integrate and correlate obtained biological data with collected radiomic and clinical information, to outline a precise PCNS-DLBCL multiomic profile and to investigate unraveled genes or cellular pathways, potentially useful for diagnostic, predictive, and therapeutic purposes. Hierarchical clustering analysis will be performed to identify genetic driver alterations and discover any subsets of tumors with distinctive multiomic (genetic/transcriptomic/radiomic) signatures.
Adults patients with primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of non-GC phenotype
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of mutations, copy number abnormalities, and structural variants
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic methylation profile
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of molecular features of clinical, laboratory, and radiological features
Time frame: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL immunological signatures defined by gene expression profiling
Time frame: 12 months: from the end of samples collection to the end of study analysis
3. Prevalence of PCNS-DLBCL MicroRNA signatures defined by miRNOMA evaluation
Time frame: 12 months: from the end of samples collection to the end of study analysis
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
International Extranodal Lymphoma Study Group (IELSG)